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BACKGROUND: Preoperative variables can predict short term left ventricular assist device (LVAD) survival, but predictors of extended survival remain insufficiently characterized.
METHOD: Patients undergoing LVAD implant (2012-2018) in the Intermacs registry were grouped
according to time on support: short-term (<1 year, n = 7,483), mid-term (MT, 1-3 years, n = 5,976) and
long-term (LT, ≥3 years, n = 3,015). Landmarked hazard analyses (adjusted hazard ratio, HR) were
performed to identify correlates of survival after 1 and 3 years of support.
RESULTS: After surviving 1 year of support, additional LVAD survival was less likely in older (HR
1.15 per decade), Caucasian (HR 1.22) and unmarried (HR 1.16) patients (p < 0.05). After 3 years of
support, only 3 preoperative characteristics (age, race, and history of bypass surgery, p < 0.05) correlated with extended survival. Postoperative events most negatively influenced achieving LT survival.
In those alive at 1 year or 3 years, the occurrence of postoperative renal (creatinine HR MT = 1.09; LT
HR = 1.10 per mg/dl) and hepatic dysfunction (AST HR MT = 1.29; LT HR = 1.34 per 100 IU), stroke
(MT HR = 1.24; LT HR = 1.42), infection (MT HR = 1.13; LT HR = 1.10), and/or device malfunction
(MT HR = 1.22; LT HR = 1.46) reduced extended survival (all p ≤ 0.03).
CONCLUSIONS: Success with LVAD therapy hinges on achieving long term survival in more recipients.
After 1 year, extended survival is heavily constrained by the occurrence of adverse events and postoperative end-organ dysfunction. The growth of destination therapy intent mandates that future LVAD
studies be designed with follow up sufficient for capturing outcomes beyond 24 months.
J Heart Lung Transplant 2022;41:161−170
Ó 2021 International Society for Heart and Lung Transplantation. All rights reserved.

Abbreviations: AE, Adverse event; cfLVAD, continuous flow left ventricular assist device; HF, heart failure; Intermacs, Interagency Registry for
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Continuous flow left ventricular assist device (cfLVAD)
therapy improves survival in carefully selected patients
with stage D heart failure (HF) with reduced ejection fraction.1−3 One-year survival in the 2020 Society of Thoracic
Surgeons (STS) Interagency Registry for Mechanically
Assisted Circulatory Support (Intermacs) report was 82%.4
While long-term survival has improved over time, only
43% of Intermacs patients are alive on durable cfLVAD
therapy at 5 years.4 Although the hazard for mortality after
cfLVAD is highest in the first 90 days after implant, the
hazard for major adverse events (AEs) during prolonged
cfLVAD support continues to increase, contributing to both
longer-term patient morbidity and mortality.5 With destination therapy (DT) and bridge to candidacy indications representing the vast majority of United States cfLVAD
implants in the contemporary era,4 it is imperative that the
field continues to identify patient-specific and device-specific factors impairing truly long-term survival. This will, in
turn, define patient management strategies and novel device
technologies that mitigate identified risks and improve
long-term outcomes.
Several studies have identified predictors of cfLVAD
mortality, but analyses have either focused on 12-24 month
patient survival or were potentially skewed by factors more
likely to influence operative, and not long term, survival.1
−3,6,7
Short-term success with cfLVAD therapy is heavily
influenced by patient selection, as well as surgical technique and the occurrence of early perioperative complications. Preoperative laboratory tests (such as creatinine,
albumin, INR and bilirubin), Intermacs profile, and hemodynamic signs of right HF have been shown to help predict
operative mortality.6−9 However, no study has consistently

shown that these same variables can forecast outcomes in
operative survivors years after device implantation.
The aim of the analysis herein is describe the pre- and
postoperative characteristics of patients enrolled into the
Intermacs registry that impact cfLVAD survival beyond 1and 3-years of support. In addition, we aim to investigate
the differential impact of AEs on subsequent survival in
cfLVAD patients achieving the 1-year and 3-year support
milestones. We hypothesize that preoperative patient characteristics will poorly predict survival after 1 year of
cfLVAD support, and that extended survival during
cfLVAD support will be greatly influenced by AEs that
accrue during support.

Patients and methods
This was a retrospective cohort analysis of adult patients (age ≥19
years) undergoing primary cfLVAD implant (n = 17,463) from
May 2012 through December 2018 in Intermacs. Follow-up ended
June 2019. Patients undergoing biventricular support (n = 684)
during the index operation and those on isolated right ventricular
assist device support (RVAD, n = 11) and total artificial heart support (n = 294) were excluded. The final cohort consisted of 16,474
patients on durable cfLVAD support. Patients were then placed
into groups according to duration of cfLVAD support (Figure 1):

1) Short-term (ST) (supported <1 year): The ST group
included patients alive with a device in place for <1
year, those who died within 1 year of cfLVAD implant,
or those who underwent device explant for transplant or
recovery within 1 year.
2) Mid-term (MT) (supported 1-3 years): Patients in the
MT group were on cfLVAD between 1 and 3 years.

Figure 1
Intermacs subgroups according to duration of cfLVAD support. Patients were sub-grouped according to survival on cfLVAD
support. Patients on mid-term support (MT) were alive on support 1-3 years and those on long-term support (LT) were alive on support for
≥3 years. Y, years. cfLVAD, continuous flow left ventricular assist device.
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
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Patients included those who were alive on device support for 1-3 years or those that died or had their device
explanted for transplant or recovery between years 1-3.
3) Long-term (LT) (supported ≥3 years): Patients were
alive on device support at the 3-year landmark.
Frequencies of major AEs were tallied for each patient and
grouped according to the patient’s duration of cfLVAD support.
Intermacs definitions from STS Intermacs User’s Guide version
(v) 5.0 were used for all AEs except right HF.10 Events classified
according to v3.0 or v4.0 were individually mapped to v5.0 definitions as shown in Supplementary Table 1. Because the outcome of
interest was longer-term survival, AEs were focused on nonoperative complications. Thus, AEs included stroke (hemorrhagic or
ischemic cerebrovascular events, not including transient ischemic
events), major bleeding from mucocutaneous sources (gastrointestinal or dental/nasopharyngeal causes), major infection and (separately) device-related infection (including pump and/or driveline
infection and/or blood culture positivity), right HF, and device
malfunction (major or minor). For the purposes of this analysis,
right HF was defined as need for right ventricular assist device
(RVAD) implantation outside the initial operative intervention or
clinical signs of right HF (elevated right atrial pressure, dilated
vena cava, edema, or ascites) with simultaneous requirement
for inotrope support on, or after, the 1-month postoperative
follow-up. The major causes of deaths were tallied for each survival group. Patients with a cause of death listed as right HF,
ischemic cardiomyopathy, end stage cardiomyopathy, and heart
disease were combined into a single “heart failure” cause of death
category.
The primary goal was to identify factors impeding extended
survival, defined as survival after achieving 1- and/or 3-years of
cfLVAD support (evaluated separately). Secondly, we aimed to
characterize the impact of major AEs on extended cfLVAD survival. Finally, we wished to identify the most common causes of
death within the group of patients dying in the MT and LT periods.
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death. Potential covariates were chosen a priori. All potential
covariates had less than 20% missing and missing values were set
to the mean. Postoperative laboratory values included in the analyses were those entered into the Intermacs registry closest to the 1and 3-year survival landmarks. Postoperative AEs were included
in modelling if events occurred within the first 1 year (MT+LT) or
3 years (LT) of support. Due to the notable differences in right HF
definitions captured across Intermacs eras (treated as an event
then later a condition), this variable was not reliably mappable
across Intermacs eras and subsequently omitted from multivariable analyses. Stepwise selection was used to identify statistically
significant risk factors for the final multivariable model, with a pvalue of 0.05 for covariates to enter and remain in the model. Hazard ratios were expressed with 70% confidence intervals. All analyses were performed using SAS version 9.4 software (SAS
Institute, Cary, NC).
This analysis was reviewed and approved by the STS Research
Center for Intermacs. The results and conclusions herein represent
those of the authors and not necessarily STS.

Results
The 1-, 3-, and 5-year survivals of the 16,474 patients undergoing cfLVAD support were 82%, 61%, and 43%, respectively. Of the patients (n = 8,991) who were alive with a
device in place at 1 year, the 3-, 5-, and 6-year survivals
were 75%, 53%, and 45%, respectively. Patients (n = 3,015)
who were alive with a device in place at 3 years had survivals of 70% and 60% at 5 and 6 years, respectively.
Patients were categorized according to duration on
cfLVAD support, regardless of patient outcome to allow for
general comparisons of preoperative characteristics. There
were 7,483 patients in the ST group, 5,976 in the MT group
(alive on support 1-3 years), and 3,015 in the LT group
(alive on support ≥3 years) (Figure 1). The baseline characteristics of the groups according to survival status are presented in supplementary table 2.

Statistical analysis
Data analysis was performed by the University of Alabama at Birmingham, which is the Intermacs data coordinating center for
STS. Patient characteristics were summarized using descriptive
statistics. Data are summarized as mean § standard error or standard error for continuous variables and percentage for categorical
variables. Comparisons between groups were performed using the
Student t-test for continuous variables and Chi-square test for categorical variables.
Estimated survival was calculated for the overall sample and
for patient groups using the methods of Kaplan-Meier. Log rank
testing was used for group survival comparisons. Due to inherent
differences in times at risk for events and terminated risk due to
transplant/explant in the Intermacs registry, survival for the purposes of further analyses was landmarked at 1 and 3 years, as outlined above. Patients were censored if they reached the end of the
study period. Then, risk factors for post-implant death were identified by conducting multi-phase parametric hazard modeling for
each landmarked time point at 1 and 3 years. This method has
been used extensively to identify the changing hazard profiles
post-surgery and the association of risk factors with different
phases of risk.11 Up to three phases of risk (early declining phase,
constant phase, and late phase) were evaluated. For our analysis, a
constant phase best fits the shape of the hazard for post-LVAD

Characteristics of patients dying during short-,
medium-, and long-term support intervals
Of 4921 total mortalities during the 6-year period of
analysis, there were 2693 (55%) deaths within 1 year,
1567 (32%) deaths with between 1 and 3 years of support, and 661 (13%) deaths in individuals with ≥3 years
of cfLVAD support. Table 1 shows the baseline characteristics of cfLVAD patients who died within each of the
3 time periods. Patients dying in the ST interval displayed a greater burden of typical high risk characteristics, including preoperative renal and hepatic function,
preoperative shock (Intermacs Profile 1, ECMO, ventilator support and/or renal replacement therapy), and they
had high frequencies of concomitant surgery with longer
cardiopulmonary bypass times than patients dying after 1
and 3 years of cfLVAD support.
The preoperative differences between patients dying
after 1- and 3-years of cfLVAD support were fewer.
Patients dying after 3 years of support had a lower burden
of pulmonary disease and were more likely to be male,
implanted for DT, and had less preoperative renal
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Table 1 Preoperative Characteristics and Operative Data of Patients Dying During the Short-Term (<1 year), Mid-Term (1-3 years), and
Long-Term (≥3 years) Support Periods.

Age, years
Male
BSA, m2
BMI, kg/m2
BTT, listed
Caucasian race
Severe diabetes
PVD
Solid organ cancer
Pulmonary HTN
Pulmonary disease
Hepatitis
Prior cardiac operation
CABG
CAD
Intermacs profile
1
2
3
4-7
TCS
IABP
ECMO
Inotropes
Dialysis
Ventilator
Creatinine, mg/dl
BUN, mg/dl
Albumin, g/dl
INR
AST, IU
Bilirubin, mg/dl
RA, mm Hg
PA Systolic, mm Hg
PA Diastolic, mm Hg
CO, l/min
History alcohol abuse
History drug use
Noncompliance
Married
Current smoker
Operative details
Bypass time, min
Concomitant surgery
Centrifugal HD flow (n = 5,211)
Centrifugal ML flow (n = 1,160)
Axial flow (n = 10,098)

Short-term (n = 2,693)

Mid-term (n = 1,567)

Long-term (n = 661)

p

61.7 § 0.22
78.1%
2.07 § 0.01
28.6 § 0.14
16.9%
72.0%
10.9%
6.5%
6.3%
22.3%
11.8%
1.3%
40.5%
28.1%
6.0%

60.4 § 0.30
78.8%
2.10 § 0.01
29.4 § 0.21
13.6%
68.6%
12.6%
7.2%
7.6%
26.0%
13.9%
2.5%
37.5%
26.4%
5.3%

60.5 § 0.50
81.7%
2.11 § 0.01
29.0 § 0.27
11.2%
72.6%
11.5%
5.5%
6.8%
27.4%
10.6%
2.6%
40.7%
29.7%
5.4%

0.0004
0.13
0.001
0.01
0.0001
0.04
0.24
0.30
0.28
0.003
0.04
0.005
0.13
0.24
0.60

20.3%
36.4%
30.0%
13.2%
36.5%
35.0%
7.8%
84.3%
5.3%
11.2%
1.52 § 0.01
33.4 § 0.37
3.30 § 0.01
1.35 § 0.01
56.93 § 2.67
1.61 § 0.05
14.00 §-0.21
49.97 § 0.31
24.55 § 0.19
4.29 § 0.03
6.1%
5.4%
2.9%
66.8%
4.8%

11.0%
35.6%
37.3%
16.1%
23.5%
30.0%
2.7%
82.8%
2.2%
6.1%
1.45 § 0.02
30.9 §.47
3.41 § 0.02
1.29 § 0.01
42.90 § 2.35
1.21 § 0.03
13.84 § 0.28
49.93 § 0.40
24.62 § 0.23
4.25 § 0.04
7.2%
6.8%
4.4%
63.8%
7.0%

9.8%
33.7%
35.4%
21.0%
20.8%
25.0%
1.8%
79.8%
2.0%
5.9%
1.39 § 0.02
30.9 § 0.47
3.46 § 0.03
1.32 § 0.02
41.20 § 3.67
1.21 § 0.04
13.37 § 0.42
49.78 § 0.62
24.33 § 0.37
4.15 § 0.06
8.6%
5.6%
3.3%
66.8%
4.7%

< 0.0001
0.44
<0.0001
<0.0001
<0 .0001
<0 .0001
<0 .0001
.02
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
0.004
0.0001
< 0.0001
0.43
0.97
0.81
0.13
0.05
0.13
0.03
0.13
0.01

104.28 § 1.12
47.8%
30.6%
4.0%
65.4%

92.16 § 1.16
38.5%
18.6%
0.1%
81.2%

97.85 § 2.02
39.9%
12.6%
0%
87.4%

< 0.0001
< 0.0001
<0.001

mean § standard error shown. ALT, alanine aminotransferase; BMI, body mass index; BSA, body surface area; BTT, bridge to transplant; CAD, coronary
artery disease; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CO, cardiac output; ECMO, extracorporeal membrane oxygenation; HD,
hydrodynamic; HTN, hypertension; IABP, intra-aortic balloon pump; ML, full Magnetic levitation; PVD, peripheral vascular arterial disease; RA, right atrial;
PA, pulmonary artery; TCS, temporary circulatory support.

dysfunction than patients who died after 1 year of support.
Importantly, patients dying after 3 years of support were
overall more likely than either ST or MT deaths to be categorized as Profiles 4 to 7, least likely to be Profile 1, and
had the lowest frequency of preoperative ventilator, balloon
pump, or temporary circulatory/ECMO use. Finally,

patients who died after 3 years of support were more likely
to have received an axial flow cfLVAD than those dying in
the MT and ST. The latter statistic may in part be related to
the later timeline of DT approval for centrifugal devices.
Age was statistically different between the patients who
died in the ST, MT, and LT. Thus, further analyses within
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Figure 2
Overall survival by age group for the cohort of patients alive with a device in place at 3 years after continuous flow left ventricular assist device implant. *Time 0 (circled) for the graph is 36 months post implant. Survial at 5 years was 78% (75%−81%) for ages 19 to
39 years, 71% (69%-73%) for ages 40 to 59 years, and 68% (67%-70%) for ages ≥60 years. (70% confidence interval) shown.

the entire cohort were undertaken and survival according to
age group in those alive with a device in place at 3 years is
shown in Figure 2. Individuals under the age of 40 years at
the time of cfLVAD implant had a 5-year survival (70%
confidence interval) of 78% (75%-81%) while individuals
aged 40 to 59 years and those ≥60 years had survivals of
71% (69%-73%) and 68% (67%-70%) at 5 years, respectively (p < 0.05).

Adverse events and impact on survival after 1 year
of support
For those patients alive and on cfLVAD support at 1 year,
the frequencies of adverse events occurring in the first
year following cfLVAD implant are shown in supplemental Figure 1. The impact of these AEs and/or their recurrence on subsequent patient survival is shown in Table 2
and Figure 3. Additional survival beyond the one year
milestone decreased as the number of episodes of right
HF (milrinone or RVAD ≥1 month after cfLVAD
implant), stroke, gastrointestinal-mucocutaneous bleeding, device malfunction, and infection increased in the
first year after device implant. Patients with ≥2 episodes
of stroke or pump-related infection were least likely to
survive to 5 years. While patients with a significant burden of gastrointestinal-mucocutaneous bleeding during
the first year of VAD support had better 5-year survival
(44% [42%-46%]) than those with recurrent strokes (38%
[35%-41%]) or pump-related infections (41% [39%43%]), survival was inferior when compared to those
without any gastrointestinal-mucocutaneous bleeding
events (56% [55%-57%]) during year 1 of cfLVAD support (all p < 0.05).

Correlates of extended survival in patients alive
with a device in place at 1 and 3 years
The demographics and characteristics of patients included
in the 1 year and 3 year landmarked survival analyses are
presented in Supplementary table 3 online. Multivariable
predictors of failure to achieve additional survival
(expressed as a constant phase hazard ratio) in the subgroup
of patients alive and on device support at 1 and/or 3 years
are presented in Table 3. Extended survival beyond 1 year
was less likely in patients who were of older age, obese,
Caucasian race and those with signs of right heart dysfunction on preoperative cardiopulmonary hemodynamics.
Important preoperative comorbidities in those dying after
1 year of LVAD support include a history of preoperative
pulmonary disease (HR 1.19, p = 0.01), hepatitis (HR 1.54,
p = 0.002), solid organ cancer (1.26, p = 0.01), and prior
coronary artery bypass grafting (CABG, HR 1.24, p <
0.0001). Of the social risks, patients who smoked at the
time of cfLVAD (HR 1.44, p < 0.0001) and those who
were not married (HR 1.16, p = 0.002) were less likely to
survive beyond a year of cfLVAD support. While preoperative laboratory values and Intermacs profile were not
predictive of survival (see bottom of Table 3 and Supplementary Table 4), patients suffering renal, hepatic, and
nutritional insufficiency within the first year following
cfLVAD support were less likely to achieve extended survival beyond 1 year of support on adjusted analyses.
Finally, the occurrence of AEs within the first year of support greatly reduced the likelihood of achieving extended
survival in those alive and on cfLVAD support at 1 year.
For each episode of stroke occurring in the first year,
adjusted mortality increased 42%, while each episode of
device infection or device malfunction increased the
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Survival After 1 Year of Support in Those With Adverse Events.
Survival (%) (70% confidence interval)

Events within 1st Year of Support

3 years

5 years

p

Overall survival
Right heart failure
None (n = 7,060)
1 episode (n = 1,531)
≥2 episodes (n = 400)
Mucocutaneous bleed
None (n = 6,834)
1 episode (n = 1,181)
≥2 episodes (n = 976)
Stroke, any
None (n = 8,257)
1 episode (n = 645)
≥2 episodes (n = 89)
Major Infection, any
None (n = 5,657)
1 episode (n = 2,083)
≥2 episodes (n = 1,251)
Infection, pump-related
None (n = 7,222)
1 episode (n = 1,349)
≥2 episodes (n = 420)
Device malfunction
None (n = 7,641)
1 episode (n = 1,106)
≥2 episodes (n = 244)

75% (74.2-75.3)

53% (51.8-53.6)

−
<0.001

76% (75.3-76.6)
72% (70.2-73.2)
65% (62.3-68.2)

55% (53.7-55.8)
47% (45.1-49.8)
37% (33.0-42.0)

77% (76.3-77.6)
70% (68.7-72.0)
66% (64.0-67.7)

56% (54.9-57.0)
46% (43.6-48.6)
41% (38.6-43.7)

76% (75.4-76.6)
61% (58.8-63.8)
57% (49.9-62.3)

54% (53.0-54.9)
38% (34.6-41.4)
40% (32.6-48.0)

80% (79.1-80.4)
72% (70.3-72.8)
58% (56.7-60.0)

57% (56.1-58.5)
49% (46.9-50.9)
39% (37.0-41.1)

78% (77.4-78.6)
66% (63.9-67.2)
49% (46.1-52.2)

56 (54.5-56.6)
44% (41.8-46.4)
30% (26.7-34.3)

76% (75.4-76.7)
68% (66.1-69.6)
67% (61.9-69.5)

53% (52.4-54.5)
50% (47.3-52.4)
39% (32.9-46.4)

<0.001

<0.001

<0.001

<0.001

<0.001

Survival is shown for those patients who were alive on support at 1 year according to the occurrence of no events, 1 event or ≥2 events of right heart
failure, mucocutaneous/gastrointestinal bleeding, stroke or infection occurring within 365 days of left ventricular assist device implant.

constant hazard for mortality by 19% and 22%, respectively
(all p < 0.0001, Table 3). Gastrointestinal bleeding was not
a significant predictor of mortality in adjusted analysis.
After at least 3 years of cfLVAD support, postoperative
organ dysfunction and device complications had the greatest impact on extended survival (Table 3). Specifically,
additional survival beyond 3 years was less likely in

patients with elevated postoperative creatinine, aspartate
aminotransferase (AST) and/or reduced albumin at 3 years
of follow-up. Further, each episode of stroke (HR 1.24 per
event, p = 0.01), major infection (HR 1.10 per event, p <
0.0001), and device malfunction (HR 1.46 per event,
p = 0.02) occurring in the first 3 years of support conferred
markedly inferior extended survival. The only preoperative

Figure 3
Impact of Adverse Events on Survival in those Alive and on cfLVAD Support at 1 Year. Adverse events occurring within 1
year of cfLVAD implant were categorized according to frequency with corresponding survival after 1 year shown. RHF, right heart failure.
cfLVAD, continuous flow left ventricular assist device.
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Multivariate Correlates of Mortality in Those Alive With a Device in Place at 1 and/or 3 Years Following Implant.
Mortality risk in those on support at 1 year

Risk Factors for Death

Constant Phase Hazard Ratio
(n = 8,991 at risk, n = 2,228 deaths)

p

Demographics
Age (per decade, with 50 to
1.15
<0 .0001
60 years of age as reference)
1.01
0.0059
BMI, per kg/m2
Race: Caucasian
1.22
<0.0001
Not married
1.16
0.0023
Clinical status
History of solid organ cancer
1.26
0.0051
History of hepatitis
1.54
0.0017
History of coronary artery bypass 1.24
< 0.0001
History of pulmonary disease
1.19
0.0075
Current smoker of tobacco
1.44
<0 .0001
Preimplant cardiopulmonary
hemodynamics
Pulmonary artery systolic, per
0.96
0.0092
10 mm Hg
Right atrial pressure, per 1 mm Hg 1.01
0.0001
Clinical events within 1 or 3 y of LVAD implanta
Stroke count (per event)
1.42
<0.0001
Infection count (per event)
1.13
<0.0001
Pump related infection count (per 1.19
<0.0001
event)
Device malfunction count (per
1.22
<0.0001
event)
Postoperative laboratory values obtained closest to 1 or 3-year follow upa
Total bilirubin, per mg/dl
1.19
<0.0001
BUN, per 10 mg/dl
1.07
<0.0001
AST, per 100 unit
1.29
<0.0001
Creatinine, per mg/dl
1.09
0.0008
Albumin, per g/dl
0.66
<0.0001

Mortality risk in those on support at 3 years
Constant Phase Hazard Ratio
(n = 3,015 at risk, n = 661 deaths)

pb

1.08

0.02

1.41

0.0002

1.29

0.0002

1.24
1.10

0.01
<0.0001

1.46

0.02

1.34
1.10
0.63

0.01
0.03
<0.0001

a
For the 1 year model, adverse events occurred within 1 year of device implant and labs closest to 1 year follow-up were used. For the 3 year model,
events occurred up to 3 years following implant and labs closest to 3 year follow-up were used.
b
Unless specified, p > 0.05. Right heart failure not included in models as discussed in methods.Variables entered into the models with an exit p > 0.05
included the following with full statistical output for 1 year model in Supplementary table 3: Intermacs profile; sex; body surface area; preoperative INR,
blood urea nitrogen (BUN), albumin, creatinine, total bilirubin, sodium, alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelet
count, hemoglobin, white cell count, blood type; history of alcohol abuse, drug use, noncompliance; history of stroke, valve surgery, severe diabetes, coronary disease, defibrillator present, or pulmonary hypertension; device intent; preop inotrope use; preop. systolic blood pressure, diastolic blood pressure, cardiac output, heart rate; preop mitral, tricuspid, and/or aortic insufficiency; preop. ventilator use, dialysis, extracorporeal membrane
oxygenation, temporary circulatory support, and/or balloon pump; centrifugal flow pump type; concomitant surgery; cardiopulmonary bypass time;
postop mucocutaneous bleed; postoperative hemorrhagic and/or ischemic stroke type; postoperative LDH and/or ALT; postop visual analog scale (VAS).
Abbreviations: BMI= body mass index.
The hazard ratio shown represents the constant hazard of death after surviving 1 or 3 years on device support. Detailed characteristics of patients
included in the 1 year and 3 year landmarked survival analyses are presented in online supplementary table 3.

characteristics that correlated with adverse cfLVAD survival beyond 3 years were age, a history of CABG, and
Caucasian race.

and respiratory failure were also notable contributors to
mortality in patients on cfLVAD support ≥ 3 years. The
most common causes of death in MT and ST patients
included multisystem organ failure, neurologic complications, and withdrawal of care.

Causes of death by survival group
Table 4 shows the most common causes of death in each
survival period. Patients on cfLVAD support ≥3 years were
most likely to die from neurological complications,
accounting for 15.7% of deaths in this group. “Other” was
listed as the second (15.4%) most common cause of death.
Complications such as HF (including right HF), infection,

Discussion
In this analysis, several important factors impeding longer
term survival on cfLVAD support were identified. First, the
most notable impediments to extended survival in those
alive and on support at 1 and 3 years were the occurrence of
postoperative end-organ dysfunction and device-related
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Table 4 Causes of Death in Patients on Short-Term (<1 years), Mid-Term (1-3 years) and Long-Term (≥3 years) Continuous Flow Left
Ventricular Assist Device Support.
Death with device in place <1 year
(n = 2,693 total)

Death with device in place 1-3 years
(n = 1,567 total)

Death with device in place ≥ 3 year
(n = 661 total)

Multisystem organ failure
(n = 577, 21.4 %)
Neurologic
(n = 520, 19.3%)
Withdrawal of care
(n = 379, 14.1%)
Heart failure
(n = 260, 9.7%)*
Other
(n = 186, 6.9%)
Respiratory
(n = 155, 5.8%)
Major Infection
(n = 148, 5.5%)

Neurologic
(n = 296, 18.9%)
Withdrawal of Care
(n = 204, 13.0%)
Other
(n = 199, 12.7%)
Heart failure
(n = 190, 12.1%)a
Multisystem organ failure
(n = 159, 10.1%)
Major infection
(n = 106, 6.8%)
Respiratory
(n = 89, 5.7%)

Neurologic
(n = 104, 15.7%)
Other
(n = 102, 15.4%)
Heart Failure
(n = 92, 13.9%)a
Withdrawal of care
(n = 75, 11.3%)
Multisystem organ failure
(n = 69, 10.4%)
Major infection
(n = 59, 8.9%)
Respiratory
(n = 35, 5.3%)

a

Heart failure includes right heart failure, CHF, end-stage cardiomyopathy, ischemic cardiomyopathy, and heart disease coding. LVAD, left ventricular
assist device.
Top 7 causes of death shown.

AEs, specifically stroke, infection, and device dysfunction.
Second, while preoperative characteristics including older
age, comorbidities (pulmonary disease, prior CABG, hepatitis, cancer), and BMI continue to influence outcomes in
those who survived the first year of support, the only preoperative characteristics that impacted survival after reaching
3 years of cfLVAD support were older age, prior CABG,
and Caucasian race. Finally, while age does correlate with
reduced survival, many carefully selected patients over age
60 achieved support durations over 3 years. Taken together,
these results suggest that preoperative correlates of risk are
important and necessary for predicting short-term survival
but are insufficient for forecasting longer-term success on
cfLVAD support. Since nearly half of the patients destined
for permanent support are alive at 5 years, the results suggest that clinical trial follow-up durations (presently at 24
months in most studies) are insufficient for capturing the
journey of most patients. These findings are especially
applicable to young patients reaching the 3 year support
landmark, as 78% of these individuals were alive 5 years
after device implant in Intermacs. Additionally, the results
herein support the need for future clinical trials to accurately and completely capture all the drivers of morbidity
and mortality that can impact both short- and longer-term
success on cfLVAD support. Present clinical trial outcomes
focus on composite endpoints that are limited to stroke and
device exchange. In those alive and on support at 1 and
3 years, the impact of infection and mucocutaneous bleeding on morbidity, mortality, and quality of life should also
be considered, especially if the field extends cfLVAD support into the less ill patient population.
In this analysis, AEs that accrued during cfLVAD had a
marked impact on achieving extended survival. Each episode
of stroke increased the hazard for mortality by 42% in those
alive on support at 1 year and by 24% for those alive on support at 3 years. Prior analyses have demonstrated the substantial impact of stroke on survival but have focused on shorter

support durations and/or incident stroke events. In a recent
analysis from Intermacs (2014-2018)12 and a sub-study from
the Multicenter Study of MagLev Technology in Patients
Undergoing Mechanical Circulatory Support Therapy with
HeartMate 3 (MOMENTUM 3),13 the occurrence of incident
postoperative stroke led to a significant reduction in survival
at 2 years of support. The findings herein demonstrate that
stroke occurring in patients alive out to 3 years has a negative
impact on added survival and recurrent neurologic events
(ischemic or hemorrhagic) in patients on longer term support
portends poor outcomes. Similarly, requirements for device
exchange due to cfLVAD thrombosis have been shown to
confer worse outcomes in the first two years of cfLVAD support.14−16 In this analysis, the occurrence of any pump malfunction reduced survival beyond 1 and 3 years by 22% and
46%, respectively. While stroke and device malfunction
appear to occur at lower frequencies in patients supported
with third generation centrifugal flow devices,1,17 results
from Intermacs or clinical trials with extended follow-up are
warranted given the marked impact of these AEs on long
term success. Furthermore, dedicated studies aimed specifically at stroke mitigation through improvements in patient
management are necessary.
The contributions of other AEs, such as mucocutaneous
bleeding, right HF, and infection, to reduced long-term survival were also unveiled in this analysis. Longer term survival is reduced in those with early (within 1 year) or later
(within 3 years) events and those with recurrent events
(Figure 3). Each episode of infection was associated with a
10% to 13% increase in the adjusted continuous hazard for
long-term mortality after 1 and 3 years of cfLVAD support,
and survival in those with recurrent right HF and mucocutaneous bleeding events was significantly reduced on unadjusted analyses. Others have shown through AE pattern
mining that there is a potential for interdependence between
AEs that occur during cfLVAD support, such that the
occurrence of one AE may be a risk for subsequent adverse
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outcomes of the same or different type.18 Even in this large
national registry, the ability to capture the full impact of
these complications with sufficient granularity for morbidity and mortality assessment was limited (infection, right
HF, mucocutaneous bleeding) or not possible (aortic insufficiency). Likewise, the impact of these AEs on patient
quality of life remains poorly characterized.17,19 Thus,
future studies of long-term cfLVAD support should focus
on the impact of individual, recurrent, and coincident complications on mortality, functional capacity, and patient
reported outcome measures.
Finally, this analysis showed that the ability to forecast
longer-term survival in the preoperative setting was very
limited. Older age is commonly identified as a risk factor
for adverse outcome after cfLVAD implant and age likely
correlates with an increased burden of comorbidities that
can impact survival. Importantly, however, the results
herein also show that advanced age should not be the only
exclusion for device implant. Nearly 60% of patients in this
analysis with extended survival on cfLVAD support were
over age 60 at implant, suggesting that careful selection is
driving success in this patient demographic for whom transplant options may be fewer. Over two thirds of patients
≥60 years of age who were alive and on cfLVAD support
at 3 years remained alive and on support at 5 years. Reasons
for inferior longer term survival in Caucasians and those
with prior CABG are not clear. Other studies have also correlated worse cfLVAD outcomes in those with prior cardiac
surgery,20 but the impact of race on cfLVAD survival has
not been consistent.21−23 Whether the correlations herein
are also associated with causation cannot be gleaned from
this study. We hypothesize that findings may be reflective
of unmeasured concomitant medical or social risks and not
directly due to race or CABG alone. Finally, while Intermacs Profile was not an independent predictor of survival
in those on longer-term LVAD support, it is important to
note that the highest frequencies of Profiles 4 to 7 were in
the long-term survival group. These findings are favorable
for extension of cfLVAD support into the less ill but randomized trials with modern devices are warranted. Since
patients categorized as Profiles 4 to 7 are, by definition, less
ill, it will be important to address the comorbidity burdens
to ensure the field’s tenured success in this population.

Limitations
It is important to acknowledge the limitations of the present
analysis. We lacked sufficient data on postoperative functional capacity and patient reported outcome measures to
examine the impact of morbidities on quality of life during
long-term cfLVAD support. This may be particularly important for mucocutaneous bleeding, which tends to be recurrent.
Intermacs compiles thousands of pre- and postoperative variables but detailed descriptions and tallying of many preoperative comorbidities (such as “severe diabetes” and
“pulmonary disease”) and psychosocial health risks are presently lacking. For example, preoperative pulmonary disease
and unmarried social status were associated with increased
mortality in those alive on support at 1 year but the severity
of pulmonary disease and impact of other social support
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systems (partnered, family support) are not known. In Intermacs User’s Guide version 6.0, we can anticipate the assignment of definitions for medical comorbidities (pulmonary,
diabetic, and renal dysfunction) which may help in the elucidation of postoperative risk in future study. The new Intermacs version will also better capture urgent transplant due to
device complications, a granular endpoint lacking in this
analysis. Importantly, right HF was excluded from the multivariable analysis due to the complexity of mapping the different definitions applied over time within Intermacs. Likewise,
the impact of aortic insufficiency leading to right HF and/or
readmission was not able to be examined herein. Certainly,
the impact of right HF and/or aortic insufficiency on morbidity and mortality during long-term cfLVAD support is underappreciated in this analysis given the high frequency of
multi-system organ failure and HF as documented causes of
death. Finally, the data herein largely captures longer term
support on HeartMate II (65% of sample) and HVAD (30%
of sample) technologies implanted temporally according to
Food and Drug Administration indications for use. While
stroke and pump thrombosis risks appear lower with centrifugal flow technologies,1,24 it is not clear that the newer technologies confer a clinically significant reduction in infection,
bleeding, and/or right HF risks. Future Intermacs reports will
shed light on these questions the impact of new technologies
and contemporary experience on long-term survival.

Conclusion
While careful preoperative patient risk stratification is important, longer-term survival after cfLVAD implant is most
greatly influenced by the patient’s postoperative course and
the development of device-related complications and endorgan dysfunction. Our analysis shows that the “Achilles
heel” of current-era cfLVAD support continues to be stroke,
infection, and cfLVAD malfunction. While clinical trial data
from newer cfLVAD systems have shown improvements in
hemocompatibility (notably pump thrombosis and stroke),
real-world data with extended patient follow-up will be
important for understanding all the contributors to extended
survival and quality of life on cfLVAD support. Further
advances in device engineering leading to improved system
(motor, outflow, and controller) durability, hemocompatibility, and the advent of fully implantable technology will be
required for cfLVAD support to truly compete with cardiac
transplant for long term survival. Until then, careful preoperative patient selection and close clinical monitoring are
obligatory for early detection and treatment of complications
that can impair long term cfLVAD success.

Disclosure statement
Conflict of interest:
Hariri: none
Dardas: none.
Kanwar: Abiomed advisory board.
Cogswell: Abbott Lab (speaker’s bureau), Medtronic −
advisory board, husband’s employment
Gosev: Abbott (consultant, speaker)
Molina: Abbott (consultant, speaker)

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 10, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

170

The Journal of Heart and Lung Transplantation, Vol 41, No 2, February 2022

Myers: Employed by the DCC for STS Intermacs.
Kirklin: I serve as Director of the Data Coordinating
Center for the STS Intermacs Database and receive partial
salary support through funds paid to my institution.
Shah: Merck, Bayer, Abbott, Medtronic, AHA / Enduring Hearts (grant support), Procyrion, NuPulseCV, Ortho
Clinical Diagnostics (consultant); Dr. Shah is supported
under NIH K23- 1K23HL143179-01A1
Pagani: FineHeart, Inc., Scientific Advisory Board;
National Heart, Lung and Blood Institute; PumpKIN Trial,
Member Data Safety Monitoring Board; Abbott, Inc., Institutional contractual clinical trial research
Cowger: Abbott and Medtronic (consultant, speaker,
institutional clinical trial funds); Procyrion (consultant,
steering committee member, institutional clinical trial
funds); Cordella Endotronix (consultant, steering committee member, institutional clinical trial funds)
Financial support: Intermacs data prior to 2018 was
supported by NHLBI grant HHSN2682011000250. Drs.
Cowger, Cogswell, and Molina, Shah, and Gosev are consultants and/or speakers for Abbott, Inc and their institutions receive clinical trial funds. Dr. Cogswell is an advisor
for Medtronic and her husband is a Medtronic employee.
Dr. Kanwar is on the Abiomed advisory board. Dr. Cowger
is also on the advisory board and/or steering committee for
Medtronic (for HVAD), Procyrion and Cordella-Endotronix
and her institution receives clinical trial funds from
Medtronic. Dr. Shah also receives funds from Medtronic,
Merck, Bayer, NuPulse, and Ortho Clinical Diagnostics. He
receives support from NIH K23- 1K23HL143179-01A1.
Dr. Pagani is on the scientific advisory board for FineHeart
and has an institutional contract for research with Abbott.
Dr. Kirklin and Susan Myers receive partial salary support
from the STS in their role in the DCC. Drs. Hariri and Dardas have no conflicts of interest to report.

Supplementary materials
Supplementary material associated with this article can be
found in the online version at https://doi.org/10.1016/j.hea
lun.2021.07.011.

Supplementary data
Supplementary data associated with this article can be
found in the online version at www.jhltonline.org/.

References
1. Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left
ventricular assist device - Final Report. N Engl J Med 2019;380:161827.
2. Milano CA, Rogers JG, Tatooles AJ, et al. HVAD: The ENDURANCE supplemental trial. JACC Heart Fail 2018;6:792-802.
3. Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med
2017;376:451-60.
4. Molina EJ, Shah P, Kiernan MS, et al. The society of thoracic surgeons
intermacs 2020 Annual Report. Ann Thorac Surg 2021;111:778-92.

5. Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events.
J Heart Lung Transplant 2017;36:1080-6.
6. Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in
patients receiving continuous flow left ventricular assist devices: the
HeartMate II risk score. J Am Coll Cardiol 2013;61:313-21.
7. Kanwar MK, Lohmueller LC, Kormos RL, et al. A bayesian model to
predict survival after left ventricular assist device implantation. JACC
Heart Fail 2018;6:771-9.
8. Birati EY, Hanff TC, Maldonado D, et al. Predicting long term
outcome in patients treated with continuous flow left ventricular
assist device: the Penn-Columbia risk score. J Am Heart Assoc
2018;7:e006408.
9. Cowger JA, Grafton G. Candidate selection for durable mechanical
circulatory support. Cardiol Clin 2018;36:487-94.
10. STS Intermacs Database. Appendix A Adverse Event Definitions.
Accessed January 15, 2020. https://www.uab.edu/medicine/intermacs/
intermacs-documents
11. Blackstone E, Naftel D, Turner M. The decomposition of time-varying
hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc 1986;81:615-24.
12. Kirklin JK, Naftel DC, Myers SL, Pagani FD, Colombo PC. Quantifying the impact from stroke during support with continuous flow ventricular assist devices: An STS INTERMACS analysis. J Heart Lung
Transplant 2020;39:782-94.
13. Colombo PC, Mehra MR, Goldstein DJ, et al. Comprehensive analysis
of stroke in the long-term cohort of the MOMENTUM 3 Study. Circulation 2019;139:155-68.
14. Kirklin JK, Naftel DC, Pagani FD, et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS
Registry. J Heart Lung Transplant 2015;34:1515-26.
15. Cowger JA, Romano MA, Shah P, et al. Hemolysis: a harbinger of
adverse outcome after left ventricular assist device implant. J Heart
Lung Transplant 2014;33:35-43.
16. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt
increase in left ventricular assist device thrombosis. N Engl J Med
2014;370:33-40.
17. Goldstein DJ, Naka Y, Horstmanshof D, et al. Association of clinical
outcomes with left ventricular assist device use by bridge to transplant
or destination therapy intent: the multicenter study of MagLev technology in patients undergoing mechanical circulatory support therapy
with HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.
JAMA Cardiol 2020;5:411-9.
18. Movahedi F, Kormos RL, Lohmueller L, et al. Sequential pattern mining of longitudinal adverse events after Left Ventricular Assist Device
implant. IEEE J Biomed Health Inform 2020;24:2347-58.
19. Cowger J. Quality of life and functional capacity assessment after
mechanical circulatory support: divergent study results exemplify the
need for standardized and dedicated studies on non-mortality endpoints. J Card Fail 2016;22:806-7.
20. Mehta P, Imamura T, Juricek C, et al. Combined left ventricular assist
device and coronary artery bypass grafting surgery: should we bypass
the bypass? ASAIO J 2020;66:32-7.
21. Birks EJ, McGee EC Jr., Aaronson KD, et al. An examination of survival by sex and race in the HeartWare Ventricular Assist Device for
the Treatment of Advanced Heart Failure (ADVANCE) Bridge to
Transplant (BTT) and continued access protocol trials. J Heart Lung
Transplant 2015;34:815-24.
22. Meeteren JV, Maltais S, Dunlay SM, et al. A multi-institutional
outcome analysis of patients undergoing left ventricular assist
device implantation stratified by sex and race. J Heart Lung
Transplant 2017;36:64-70.
23. Ueyama H, Malik A, Kuno T, et al. Racial disparities in in-hospital
outcomes after left ventricular assist device implantation. J Card Surg
2020;35:2633-9.
24. Teuteberg JJ, Cleveland JC Jr., Cowger J, et al. The Society of
Thoracic Surgeons Intermacs 2019 Annual Report: the changing
landscape of devices and indications. Ann Thorac Surg 2020;109:
649-60.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 10, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

